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Abstract
Background: The success of the microarray process in determining differential gene expression
of thousands of genes is dependent upon the quality and integrity of the starting RNA, this being
particularly true of direct labeling via a reverse transcription procedure. Furthermore, an RNA of
reasonable quality still may not yield reliable hybridization data if the labeling efficiency was poor.
Results: Here we present a novel assay for assessing the quality of directly labeled fluorescent
cDNA prior to microarray hybridization utilizing the Agilent 2100 Bioanalyzer, which employs
microfluidic technology for the analysis of nucleic acids and proteins. Using varying amounts of
RNase to simulate RNA degradation, we show the strength of this un-advertised assay in
determining the relative amounts of cDNA obtained from a direct labeling reaction.
Conclusion: Utilization of this method in the lab will help to prevent the costly mistake of
hybridizing poor quality direct labeled products to expensive arrays.
Background
The use of cDNA and oligonucleotide microarray technol-
ogy has revolutionized the fields of molecular biology,
biochemistry and genetics. The ability to simultaneously
evaluate gene expression across tens of thousands of genes
gives researchers opportunities not previously afforded to
them.
RNA extractions have proven to be of large concern for
evaluating messenger RNA transcript levels by microarrays
and other procedures such as RT-PCR, RNase protection
assays and Northern blot analyses. Extraction procedures
are still evolving and adapt to meet different needs, such
as for pure cell populations [1]. Differences between two
RNA extractions from the same source material have been
shown to make a significant contribution to technical var-
iance in microarray data [2].
Microarray technology utilizes various protocols based in
part on reverse transcription and PCR technologies [3,4].
Direct labeling protocols use modified deoxyribonucle-
otide phosphates (dNTPs) incorporated during a reverse
transcription reaction, in which mRNA is copied into
cDNA. One possible modification to the dNTPs is the
addition of an amino-propagyl cyanine (Cy) fluorescent
molecule at the 5-carbon of the pyrimidine base [5,6]. For
cDNA and oligonucleotide microarrays, Cy3 and Cy5 are
commonly used fluorescent dyes that are excited by
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different wavelengths of light. Therefore they can be used
in combination, one labeling a control or reference sam-
ple and the other labeling the treatment or test sample.
After combining the two labeled cDNA samples and
hybridizing to a microarray chip, gene expression can be
extrapolated from the ratio of the two different cyanine
dye fluorescences detected. The entire microarray process,
especially the reverse transcription labeling procedure, is
dependent upon the quality and integrity of the starting
RNA.
The Agilent 2100 Bioanalyzer, first described for the inves-
tigation of DNA, employs microfluidic technology for the
analysis of nucleic acids and proteins [7]. A total RNA
assay determines a numerical value for the ratio of 28S
ribosomal RNA (rRNA) subunit to 18S rRNA subunit,
while an mRNA assay determines the percentage of rRNA
contamination. To measure ribosomal subunit concentra-
tions, RNA is combined with a sample buffer containing a
fluorescent dye that intercalates into the RNA and is
excited by an internal 635 nm diode laser. Data output is
in the form of an electropherogram, which graphically
depicts spikes in fluorescence over time; the larger the
peak, the more intact ribosomal subunits are in the sam-
ple. If a sample is degraded, subunits will show a smaller
degree of fluorescence that is spread out over a longer
amount of time, indicating a greater variety of sizes in the
sample. Auer and colleagues recently published the "deg-
radation factor" utilizing data obtained using the RNA
assay of the Bioanalyzer as a more quantitative approach
[8]. This approach calculates a ratio between the 18S
ribosomal peak area and the average of the peaks smaller
than the 18S ribosomal peak that are indicative of degra-
dation. The authors show that RNA isolations which
exhibit similar degradation factors are more likely to give
gene expression results that are more biologically relevant
than comparing two RNA isolations with differing degrees
of degradation.
The quality and integrity of RNA samples can be evaluated
by gel electrophoresis, UV spectrophotometry and the
Agilent Bioanalyzer. From one or a combination of these
methods, assessments of how well an RNA sample may
perform in a reverse transcription labeling reaction and
subsequent microarray chip hybridization can be made.
Unfortunately, the cDNA reverse-transcribed from an
RNA of reasonable quality may not yield reliable products
after the labeling steps and lead to poor hybridization
results. Our lab has experienced this problem as a result
of, among others, possible genomic DNA contamination
of the RNA sample. This problem with the RNA is difficult
to detect with an RNA assay on the Bioanalyzer, and the
contamination will likely impact the quality of any labe-
ling reaction the sample is used in, regardless of the
fluorophore.
Agilent currently promotes the use of their instrument for
measuring Cy-labeled cRNA obtained from an amplifica-
tion protocol. They do not, however, currently have a pro-
tocol to measure the quality of Cy-labeled cDNA from a
direct labeling protocol. To address and avoid the loss of
time and money associated with a failed microarray anal-
ysis, we present a novel use for the Agilent 2100 Bioana-
lyzer in determining the relative quantity and quality of
direct-labeled products obtained during the labeling reac-
tion. By comparing with cDNA obtained from known
high quality RNA, we can determine how well the cyanine
dye was directly incorporated during reverse transcription,
and thus if reliable microarray data can be obtained.
Results and discussion
Using an Agilent Bioanalyzer, typical indications of high
quality, intact total RNA samples are electropherograms
with flat baselines and a relatively flat valley between the
two strong fluorescent rRNA peaks (Figure 1A, No RNase).
An important note is that within the context of a high
quality total RNA sample, the mRNA fluorescence is
below detection. mRNA normally accounts for only 1–5%
of a total RNA sample [9] and the rRNA peaks dominate
the fluorescence of these samples. The undegraded total
RNA sample shows distinct 18S and 28S rRNA subunit
spikes, with a ratio of 1.85 ([28S]: [18S]). This ratio, along
with the contours of the electropherogram, led to the con-
clusion that this was an undegraded, high quality RNA
sample. Treatment with 1 ng ml-1 RNase degrades essen-
tially all RNA present, as evidenced by its lack of 18S and
28S rRNA peaks (Figure 1D, 1 ng ml-1 RNase). Concentra-
tions of RNase less than 1 ng ml-1 only partially degrade
the RNA samples since 18S and 28S peaks are detectable
but less than optimal (compare Figure 1A with 1B and 1C,
No RNase with 100 ng ml-1 and 10 ng ml-1 RNase,
respectively).
Fully degraded, partially degraded and intact RNA, gener-
ated by titrating varying amounts of RNase, were used to
prepare samples for measuring Cy5 incorporation directly
into the cDNA by reverse transcription of RNA by the Agi-
lent 2100 Bioanalyzer. It should be noted, however, that
RNase treatment can be unpredictable, since even slight
deviations in temperature and timing of incubation can
result in varying degrees of degradation. Over triplicate
experiments, individual treatments could vary over 100%
from day to day, however the overall trends do not
change.
Cy5-dUTP was directly incorporated by reverse transcrip-
tion into the intact (No RNase) sample as well as the three
RNase treated samples. Since the RNA is hydrolyzed after
reverse transcription, only the cDNA detectable. Analysis
of the Cy5 signal obtained from an intact RNA sample
(Figure 1E, pink trace), as measured by the Bioanalyzer,BMC Genomics 2005, 6:36 http://www.biomedcentral.com/1471-2164/6/36
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RNA and Cy5-dUTP labeled cDNA measured by the Agilent 2100 Bioanalyzer Figure 1
RNA and Cy5-dUTP labeled cDNA measured by the Agilent 2100 Bioanalyzer. Electropherogram images (one rep-
resentative experiment) of RNAs treated with RNase as follows: No RNase (A, pink), 0.01 ng ml-1 (B, blue), 0.1 ng ml-1 (C, 
red), 1 ng ml-1 (D, green). Overlayed electropherogram image of Cy5-dUTP labeled cDNA (E, colors as described above, one 
representative experiment). The first peak (as shown by an arrow) from the left in all electropherograms is a 50 base pair 
marker present in the sample buffer (M). The second peak (as shown by an arrow) that is present only in Cy5 samples is free 
Cy5-dUTP (Cy5) and measures approximately 150 nucleotides (data not shown). Though it is a single nucleotide, the Cy5 
modification is large, which could explain its delayed migration and detection.BMC Genomics 2005, 6:36 http://www.biomedcentral.com/1471-2164/6/36
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reveals a distribution of different transcript sizes. Along
with a wide distribution of sizes, the overall fluorescence
is much higher for the undegraded sample as compared to
the RNase-treated samples (blue, red and green traces for
0.01, 0.1 and 1 ng ml-1 RNase, respectively, Figure 1E).
The Cy5-labeled cDNA concentration, calculated by the
Bioanalyzer assay as the area under the curve in Figure 1E,
decreases approximately 65% after treatment with 1 ng
ml-1 RNase and 30% with 0.1 ng ml-1 RNase. Treatment
with 0.01 ng ml-1 RNase also depleted Cy5-labeled cDNA
concentration, though only by about 25%. These Bioana-
lyzer results show considerable reductions in Cy5-labeled
cDNA signal obtained, due to the degraded nature of the
RNA samples.
Gel electrophoresis, such as small scale poly-acrylamide
analysis [10], has been used to determine characteristics
of Cy5 incorporation. As shown in Figure 2, the phos-
phorimager scan of an agarose gel and the "gel-like
image" obtained from the Bioanalyzer visually depict
common trends. However, performing the gel electro-
phoresis was more sample- and time-consuming. Further-
more, quantitation was more subjective since
measurement areas must be user-defined. The coefficients
of variation, though intrinsically high because of the
RNase treatment itself, were higher for the gel electro-
phoresis analysis.
Further validation of this assay came from analyzing RNA
samples that had previously been labeled and hybridized,
but provided poor quality expression data. These RNAs,
based on Bioanalyzer electropherograms similar to that of
the intact RNA in Figure 1A, appeared to be of high quality
with 18S:28S peak ratios in excess of 1.8. To test the new
assay, the labeling reactions were performed again and the
labeled products produced were assessed on the Bioana-
lyzer and hybridized to the NIEHS Human ToxChip.
As shown in Figure 3A, each of these test samples show a
marked decrease in the total fluorescence measured by the
Bioanalyzer as compared to the control samples, which
were derived from RNA that had previously performed
well in microarray labeling and hybridization procedures.
Additionally, comparison of average array intensity for
each of the test samples is dramatically reduced when
compared with arrays hybridized with product from
MCF7 intact RNAs (Figure 3B). We believe that there was
possible genomic DNA contamination, as evidenced by
non-migratory nucleotides in the wells of a formaldehyde
gel (data not shown) It has been implicated that DNA
contamination causes a decrease in efficiency of the labe-
ling procedure [11], though other contaminants inherent
to RNA extraction, such as phenol, or inherent to the RNA
sample (high lipid or protein content) may also interfere.
Though first thought to be of ideal quality for microarray,
these human lung fibroblast test samples have been
shown through the application of this novel assay to be
less than optimal for use on a microarray chip. Had this
assay been used prior to hybridization in previous experi-
ments, the money and time spent in putting these direct
labeled products on a chip would have been saved.
Conclusion
From this novel Bioanalyzer assay, we are able to deter-
mine if a sample of questionable integrity is "chip wor-
thy" or not. Selection criteria are subjective since the
quality requirement will differ for different platforms.
Determining the integrity of a sample could save an inves-
tigator a significant amount of capital resources (compare
the tens of dollars that a Bioanalyzer chip costs to the hun-
dreds of dollars in expenses for a microarray hybridiza-
tion). The Agilent 2100 Bioanalyzer provides a cost-
efficient way to determine an RNA, and the subsequent
cDNA, sample's ability to provide high quality data (wide
dynamic range) for a microarray chip. Though not meant
as an absolute quantitative tool, trends in labeling effi-
ciency can be assessed using this novel method. This assay
can be used in place of conventional gel electrophoresis
because it is more time and sample efficient, and it is con-
siderably more cost effective than microarray hybridiza-
tions. In the future, we plan to use this assay to as a
screening tool for direct labeled products prior to
hybridization.
Methods
Standard protocols can be accessed at http://
dir.niehs.nih.gov/microarray/methods.htm.
RNA preparation and degradation
Total RNA was prepared from logarithmically growing
immortalized human mammary cells (MCF-7) using the
RNeasy kit (Qiagen, Valencia, CA, USA) according to the
manufacturer's instructions. RNA concentration and
purity were estimated spectrophotometrically and the
quality further assessed with the Agilent 2100 Bioanalyzer
(Palo Alto, CA, USA). This intact RNA was split into aliq-
uots and treated with varying concentrations of RNase A
(0, 1, 0.1 and 0.01 ng ml-1). After incubation at 37°C for
10 minutes, RNA was analyzed for post-treatment quality
assessment using the Bioanalyzer. The samples were
loaded at 100 ng per well based on the original concentra-
tion values obtained by the spectrophotometer. The Agi-
lent 2100 Bioanalyzer uses a 635 nm diode laser with an
emission filter of 670–700 nm to detect fluorescence after
dye intercalation into nucleic acids.
Total RNA was also prepared from human keratinocytes
(Hacat) and human lung fibroblasts (16Lu) (American
Type Culture Collection, Manassas, VA, USA) using the
RNeasy kit (Qiagen, Valencia, CA, USA) according to theBMC Genomics 2005, 6:36 http://www.biomedcentral.com/1471-2164/6/36
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Comparison of Bioanalyzer assay with conventional gel analysis Figure 2
Comparison of Bioanalyzer assay with conventional gel analysis. A- cDNAs were separated based on size using a 1% 
agarose gel. Red fluorescence (650 long pass emission filter) was measured using a Storm phosphorimager and quantitated 
using IMAGEQuant. B- "Gel-like" images obtained from the Bioanalyzer are digital images rendered from conversion of electro-
pherogram fluorescence traces using the Bioanalyzer software. Both images are the same sample from one representative 
experiment ran in parallel.BMC Genomics 2005, 6:36 http://www.biomedcentral.com/1471-2164/6/36
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Practical application of the Cy5-cDNA Bioanalyzer assay Figure 3
Practical application of the Cy5-cDNA Bioanalyzer assay. (A) Overlayed electropherogram image of Cy5-dUTP 
labeled cDNA obtained from control RNAs (MCF7 and HACAT, red and blue traces, respectively) and from test samples 
(Test #1 and Test #2, brown and purple traces respectively). First and second sharp peaks are as described in legend for Figure 
1. (B) Average microarray intensity for MCF7, Test 1 and Test 2. Error bar is standard error from three arrays. Test samples 
were hybridized to only one microarray each.
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manufacturer's instructions. RNA concentration and
purity were estimated spectrophotometrically and the
quality further assessed with the Agilent 2100 Bioanalyzer
(Palo Alto, CA, USA).
Direct Cy5-dUTP incorporation for RNase-treated 
samples
Each total RNA sample (35 µg, post-RNase treatment) was
labeled with direct incorporation of Cyanine 5 (Cy5)-con-
jugated dUTP (Amersham, Piscataway, NJ) by a reverse
transcription reaction using the reverse transcriptase,
SuperScript II (Invitrogen, Carlsbad, CA), and an oligo dT
primer (Amersham, Piscataway, NJ). After reverse tran-
scription, RNA was degraded by alkaline hydrolysis and
excess dNTPs and enzymes from the reverse transcription
reaction were removed using a modified version of Qia-
gen's QIAquick PCR Purification procedure (addition of a
35% guanidine HCl wash). This additional wash step
occurs before the PE Buffer wash and uses the standard
750  µl volume for these columns. Following column
washes, bound cDNA was eluted according to manufac-
turer's instructions.
Direct Cy-dUTP incorporation for assay validation 
samples
Direct labelings (25 µg total RNA) by Cy3 and Cy5 were
performed with two of the 16Lu RNAs being labeled with
Cy3 and another two being labeled with Cy5. Addition-
ally, MCF7-derived RNA as well as Hacat-derived RNA,
both known to be of high quality, were labeled once per
dye and are considered as controls. After the reverse tran-
scription reactions were carried out, each Cy3/Cy5 pair
was mixed together, cleaned and eluted using the Qiagen
PCR Purification kit with modifications, as described
above.
Cy5 detection by the Agilent 2100 Bioanalyzer
For comparing the RNase-treated samples, 1 µl of the elu-
ate was mixed with 5 µl 25% Sample Buffer (200 mM
TAPS, 1 mM EDTA, pH 8.0) from the Agilent RNA 6000
Nano Kit, loaded onto an RNA LabChip (Agilent Technol-
ogies, Wilmington, DE) and detected with the Eukaryote
Total RNA Nano Assay. Size distribution, concentration
and overall amount of fluorescence were used for evalua-
tion of dye incorporation. The detected fluorescence is the
total combination of the intercalating dye and Cyanine 5.
Comparisons are made between each of the RNase treated
samples and the untreated control.
For the human lung fibroblast test samples, the Cy3 and
Cy5 samples were mixed together in preparing for the
hybridizations. We previously observed a lack of signifi-
cant contribution to the overall fluorescence on the Bio-
analyzer by Cy3-labeled samples (data not shown). Cy3
does not fluoresce in the range of the Bioanalyzer laser
and any contribution to the outcome of the test would be
minimal and yet consistent across all samples. One µl
aliquots were analyzed as described above. Quality assess-
ment was achieved by comparing the curves of the test
samples to those of control samples.
Gel electrophoresis
Five µl of each eluate was loaded onto a 1% agarose gel.
The loading dye used in this experiment (25% glycerol,
0.1 M EDTA, 0.03% Bromophenol Blue) does not autoflu-
oresce when measuring the red fluorescence and therefore
did not interfere with measurement of the Cy5-labeled
cDNA (data not shown). Red fluorescence (650 nm long
pass emission filter) was detected using a Storm phos-
phorimager and quantified with IMAGEQuant (Amer-
sham Biosciences, Piscataway, NJ).
Microarray hybridizations and analyses
Fluorescently labeled test sample and MCF7 cDNAs were
mixed with an SSC/SDS hybridization solution and
hybridized to the microarray overnight in a 65°C water
bath. The MCF7 samples were hybridized on different
days than the test samples. A cDNA Human ToxChip [12],
developed in-house at NIEHS, was used for hybridization
experiments. A complete listing of the genes on this chip
is available at the following website: http://
dir.niehs.nih.gov/microarray/chips.htm. cDNA microar-
ray chips were prepared as previously described [4,13].
The cDNA microarray chips were scanned with an Agilent
Scanner (Agilent Technologies, Wilmington, DE) using
laser excitation at 635 and 100% PMT sensitivity. The Agi-
lent scanner is useful for these comparisons because of its
ability to control laser variability, allowing data to be
compared directly from day to day. The raw pixel intensity
images were analyzed using the ArraySuite v2.0 extensions
of the IPLab image processing software package (Scanalyt-
ics, Fairfax, VA). This program uses methods that were
developed and previously described [14] to locate targets
on the array, measure local background for each target
and subtract it from the target intensity value. Data were
calculated by taking the median of spot intensities over
each chip
List of abbreviations used
RNA Ribonucleic Acid
rRNA Ribosomal Ribonucleic Acid
mRNA Messenger Ribonucleic Acid
cDNA Complementary Deoxyribonucleic Acid
PCR Polymerase Chain ReactionPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Genomics 2005, 6:36 http://www.biomedcentral.com/1471-2164/6/36
Page 8 of 8
(page number not for citation purposes)
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Reaction
dNTPs deoxy-Nucleotide TriPhosphates
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